MAR-DONEPEZIL TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
10-02-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
DONEPEZIL HYDROCHLORIDE
Beschikbaar vanaf:
MARCAN PHARMACEUTICALS INC
ATC-code:
N06DA02
INN (Algemene Internationale Benaming):
DONEPEZIL
Dosering:
10MG
farmaceutische vorm:
TABLET
Samenstelling:
DONEPEZIL HYDROCHLORIDE 10MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/500
Prescription-type:
Prescription
Therapeutisch gebied:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0131548002; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2013-12-27
Productkenmerken
Page 1 of 50
PRODUCT MONOGRAPH
Pr
MAR-DONEPEZIL
Donepezil Hydrochloride Tablets, House Std
5 and 10 mg
CHOLINESTERASE INHIBITOR
Marcan Pharmaceuticals Inc. Date of Revision:
2 Gurdwara Road, Suite 112
February 10, 2020
Ottawa, Ontario
K2E 1A2
Submission Control No.: 235582
Page 2 of 50
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
17
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
24
DETAILED PHARMACOLOGY
...................................................................
Lees het volledige document
